EA201491622A1 - Биспецифические антитела против baff и ил-17 - Google Patents
Биспецифические антитела против baff и ил-17Info
- Publication number
- EA201491622A1 EA201491622A1 EA201491622A EA201491622A EA201491622A1 EA 201491622 A1 EA201491622 A1 EA 201491622A1 EA 201491622 A EA201491622 A EA 201491622A EA 201491622 A EA201491622 A EA 201491622A EA 201491622 A1 EA201491622 A1 EA 201491622A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bispecific antibodies
- baff
- antibodies against
- against baff
- sle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Предложены биспецифические антитела, которые специфически связываются с фактором активации В-клеток из семейства ФНО (BAFF) и интерлейкином-17А (ИЛ-17), которые характеризуются высокой аффинностью и высокими нейтрализующими свойствами как в отношении BAFF, так и в отношении ИЛ-17. Ожидается, что биспецифические антитела согласно настоящему изобретению можно будет применять в лечении волчаночного нефрита (ВН), системной красной волчанки (СКВ), ревматоидного артрита (РА), псориаза (Пс), анкилозирующего спондилоартрита (АС), псориатического артрита (ПА), первичного синдрома Шегрена (пСШ) или множественной миеломы (ММ).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261636302P | 2012-04-20 | 2012-04-20 | |
US201361768747P | 2013-02-25 | 2013-02-25 | |
PCT/US2013/036677 WO2013158577A1 (en) | 2012-04-20 | 2013-04-16 | Anti-baff-anti-il-17 bispecific antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201491622A1 true EA201491622A1 (ru) | 2015-01-30 |
EA029185B1 EA029185B1 (ru) | 2018-02-28 |
Family
ID=48539373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201491622A EA029185B1 (ru) | 2012-04-20 | 2013-04-16 | Биспецифические антитела против baff и ил-17 |
Country Status (40)
Country | Link |
---|---|
US (2) | US9359448B2 (ru) |
EP (2) | EP3192809B1 (ru) |
JP (1) | JP6216772B2 (ru) |
KR (1) | KR101673735B1 (ru) |
CN (1) | CN104220455B (ru) |
AP (1) | AP2014008002A0 (ru) |
AR (1) | AR090626A1 (ru) |
AU (1) | AU2013249546B2 (ru) |
BR (1) | BR112014025649A2 (ru) |
CA (1) | CA2869148C (ru) |
CL (1) | CL2014002616A1 (ru) |
CO (1) | CO7160039A2 (ru) |
CR (1) | CR20140466A (ru) |
CY (1) | CY1118824T1 (ru) |
DK (1) | DK2838920T3 (ru) |
DO (1) | DOP2014000234A (ru) |
EA (1) | EA029185B1 (ru) |
EC (1) | ECSP14023405A (ru) |
ES (2) | ES2621917T3 (ru) |
GT (1) | GT201400217A (ru) |
HK (1) | HK1201862A1 (ru) |
HR (1) | HRP20170468T1 (ru) |
HU (1) | HUE032153T2 (ru) |
IL (1) | IL234965B (ru) |
IN (1) | IN2014MN01876A (ru) |
LT (1) | LT2838920T (ru) |
ME (1) | ME02596B (ru) |
MX (1) | MX367460B (ru) |
MY (1) | MY173282A (ru) |
NZ (1) | NZ630865A (ru) |
PE (1) | PE20142147A1 (ru) |
PH (1) | PH12014502333A1 (ru) |
PL (1) | PL2838920T3 (ru) |
PT (1) | PT2838920T (ru) |
RS (1) | RS55729B1 (ru) |
SG (1) | SG11201406726PA (ru) |
SI (1) | SI2838920T1 (ru) |
TW (1) | TWI585103B (ru) |
WO (1) | WO2013158577A1 (ru) |
ZA (1) | ZA201407272B (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102906118B (zh) | 2010-05-20 | 2017-07-28 | 埃博灵克斯股份有限公司 | 与her3相关的生物材料 |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
AR090626A1 (es) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
TW201444867A (zh) * | 2013-03-08 | 2014-12-01 | Lilly Co Eli | 抗tnf-抗il-17雙特異性抗體 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
CA2929846C (en) * | 2013-11-19 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
CN105873949A (zh) | 2014-01-31 | 2016-08-17 | 勃林格殷格翰国际有限公司 | 新的抗baff抗体 |
AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
EP3322436A4 (en) | 2015-07-23 | 2019-03-27 | Boehringer Ingelheim International GmbH | COMPOUND TARGETING THE FACTOR OF ACTIVATION OF IL-23 AND LYMPHOCYTES B (BAFF) AND USES THEREOF |
CN105061596B (zh) * | 2015-08-05 | 2019-01-29 | 江苏诺迈博生物医药科技有限公司 | 人b淋巴细胞刺激因子的单克隆抗体及其应用 |
US20200385478A1 (en) * | 2018-01-05 | 2020-12-10 | Biograph 55, Inc. | Compositions and methods for cancer immunotherapy |
CN117529506A (zh) * | 2021-06-11 | 2024-02-06 | 海南先声药业有限公司 | 抗人il-17抗体和taci的双功能融合蛋白分子 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
AR035119A1 (es) * | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
BRPI0615026A8 (pt) * | 2005-08-19 | 2018-03-06 | Abbott Lab | imunoglobulina de domínio variável duplo e seus usos |
WO2007070750A1 (en) | 2005-12-13 | 2007-06-21 | Eli Lilly And Company | Anti-il-17 antibodies |
WO2011141823A2 (en) * | 2010-05-14 | 2011-11-17 | Orega Biotech | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists |
AR090626A1 (es) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
-
2013
- 2013-04-08 AR ARP130101134A patent/AR090626A1/es active IP Right Grant
- 2013-04-12 TW TW102113167A patent/TWI585103B/zh not_active IP Right Cessation
- 2013-04-16 IN IN1876MUN2014 patent/IN2014MN01876A/en unknown
- 2013-04-16 PT PT137263216T patent/PT2838920T/pt unknown
- 2013-04-16 AU AU2013249546A patent/AU2013249546B2/en not_active Ceased
- 2013-04-16 EA EA201491622A patent/EA029185B1/ru not_active IP Right Cessation
- 2013-04-16 ME MEP-2017-41A patent/ME02596B/me unknown
- 2013-04-16 ES ES13726321.6T patent/ES2621917T3/es active Active
- 2013-04-16 KR KR1020147028867A patent/KR101673735B1/ko active IP Right Grant
- 2013-04-16 WO PCT/US2013/036677 patent/WO2013158577A1/en active Application Filing
- 2013-04-16 JP JP2015507095A patent/JP6216772B2/ja active Active
- 2013-04-16 MX MX2014012692A patent/MX367460B/es active IP Right Grant
- 2013-04-16 HU HUE13726321A patent/HUE032153T2/en unknown
- 2013-04-16 BR BR112014025649A patent/BR112014025649A2/pt not_active Application Discontinuation
- 2013-04-16 SI SI201330522A patent/SI2838920T1/sl unknown
- 2013-04-16 NZ NZ630865A patent/NZ630865A/en not_active IP Right Cessation
- 2013-04-16 AP AP2014008002A patent/AP2014008002A0/xx unknown
- 2013-04-16 US US13/863,544 patent/US9359448B2/en active Active
- 2013-04-16 LT LTEP13726321.6T patent/LT2838920T/lt unknown
- 2013-04-16 PL PL13726321T patent/PL2838920T3/pl unknown
- 2013-04-16 CA CA2869148A patent/CA2869148C/en active Active
- 2013-04-16 PE PE2014001619A patent/PE20142147A1/es active IP Right Grant
- 2013-04-16 MY MYPI2014703075A patent/MY173282A/en unknown
- 2013-04-16 SG SG11201406726PA patent/SG11201406726PA/en unknown
- 2013-04-16 DK DK13726321.6T patent/DK2838920T3/en active
- 2013-04-16 CN CN201380020761.7A patent/CN104220455B/zh active Active
- 2013-04-16 EP EP17153380.5A patent/EP3192809B1/en active Active
- 2013-04-16 RS RS20170160A patent/RS55729B1/sr unknown
- 2013-04-16 ES ES17153380T patent/ES2789474T3/es active Active
- 2013-04-16 EP EP13726321.6A patent/EP2838920B1/en active Active
-
2014
- 2014-09-30 CL CL2014002616A patent/CL2014002616A1/es unknown
- 2014-10-02 IL IL234965A patent/IL234965B/en active IP Right Grant
- 2014-10-06 CR CR20140466A patent/CR20140466A/es unknown
- 2014-10-07 ZA ZA2014/07272A patent/ZA201407272B/en unknown
- 2014-10-15 GT GT201400217A patent/GT201400217A/es unknown
- 2014-10-16 DO DO2014000234A patent/DOP2014000234A/es unknown
- 2014-10-17 EC ECIEPI201423405A patent/ECSP14023405A/es unknown
- 2014-10-17 PH PH12014502333A patent/PH12014502333A1/en unknown
- 2014-10-20 CO CO14231938A patent/CO7160039A2/es unknown
-
2015
- 2015-03-12 HK HK15102524.4A patent/HK1201862A1/xx not_active IP Right Cessation
-
2016
- 2016-05-18 US US15/157,782 patent/US9708402B2/en active Active
-
2017
- 2017-03-21 HR HRP20170468TT patent/HRP20170468T1/hr unknown
- 2017-03-27 CY CY20171100380T patent/CY1118824T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201491622A1 (ru) | Биспецифические антитела против baff и ил-17 | |
MX2015011957A (es) | Anticuerpos biespecificos anti-tnf-anti-il-17. | |
EA201890565A1 (ru) | Композиции и способы улучшения специфичности в геномной инженерии с применением рнк-направляемых эндонуклеаз | |
EP4311558A3 (en) | Antibodies that bind il-23 | |
UA117575C2 (uk) | Антитіло, яке специфічно зв'язується з il-17a та його застосування | |
EA201791422A1 (ru) | Фармацевтические продукты и устойчивые жидкие композиции антител к il-17 | |
NZ703607A (en) | Heteroaromatic compounds as bruton’s tyrosine kinase (btk) inhibitors | |
EA201690325A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ | |
MX2016002571A (es) | Regulador de ph de transduccion. | |
TR201909531T4 (tr) | Anti-il-17 anti̇korlari kullanilarak anki̇lozan spondi̇li̇t tedavi̇ etme yöntemleri̇ | |
EA201490195A1 (ru) | Не содержащие аргинина композиции слитого fc-полипептида и способы их применения | |
EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
MX2022006573A (es) | Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias. | |
EA201491471A1 (ru) | Состав, содержащий антитело против ил-17 | |
MX2016006101A (es) | Agente ligante de la il-17a y usos del mismo. | |
EA202193002A2 (ru) | Соединение, нацеленное на ил-23a и фно-альфа, и его применение | |
EA201892440A1 (ru) | Антитела к tl1a и их применения | |
TN2014000413A1 (en) | Anti-baff-anti-il-17 bispecific antibodies | |
TH1401006266A (th) | แอนติ-baff-แอนติ-il-17ไบสเปซิฟิกแอนติบอดี | |
UA113080C2 (xx) | Біспецифічне антитіло, яке специфічно зв'язується з il17 та baff | |
WO2014113431A3 (en) | Methods and compositions for targeting immunoglobulins | |
EA202090128A3 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ BY KG TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM |